EP0766558A1 - Systeme therapeutique transdermique a principes actifs constituant des sources de monoxyde de carbone - Google Patents

Systeme therapeutique transdermique a principes actifs constituant des sources de monoxyde de carbone

Info

Publication number
EP0766558A1
EP0766558A1 EP95921826A EP95921826A EP0766558A1 EP 0766558 A1 EP0766558 A1 EP 0766558A1 EP 95921826 A EP95921826 A EP 95921826A EP 95921826 A EP95921826 A EP 95921826A EP 0766558 A1 EP0766558 A1 EP 0766558A1
Authority
EP
European Patent Office
Prior art keywords
tts according
active
carbon monoxide
tts
substances
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP95921826A
Other languages
German (de)
English (en)
Inventor
Fritz Herrmann
Harald List
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LTS Lohmann Therapie Systeme AG
Original Assignee
LTS Lohmann Therapie Systeme AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LTS Lohmann Therapie Systeme AG filed Critical LTS Lohmann Therapie Systeme AG
Publication of EP0766558A1 publication Critical patent/EP0766558A1/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/295—Iron group metal compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Definitions

  • the present invention relates to a transdermal therapeutic system (TTS) for the systemic and topical administration of active substances which are suitable for increasing the carbon monoxide (CO) concentration in the organism.
  • TTS transdermal therapeutic system
  • CO has a very important role as a mediator in both physiological and pathophysiological processes in the body.
  • the role of the CO extends to the regulation of the arterial vascular tone, the platelet aggregation, the influencing of immunological and inflammatory processes as well as the function as a messenger when the excitations of the central and peripheral nervous system are transmitted.
  • CO is also involved in pathophysiological changes in these functional structures or organ systems, e.g. High blood pressure, coronary artery stenosis, arteriosclerosis; there is also evidence of involvement in immunological and inflammatory processes and influencing cell growth.
  • the function of a neurotransmitter is attributed to CO in the central and peripheral nervous system.
  • the rapid diffusion through cell membranes enables the significant role as an inter- and intracellular mediator.
  • active substances are administered to an organism through the skin or mucous membrane, of which at least one of the active substances is selected from compounds which contain carbon onoxide (CO ) release.
  • CO carbon onoxide
  • a therapeutic system is a drug-containing device or dosage form which delivers one or more medicinal substances at a predetermined rate continuously over a defined period of time at a specified application location (HEILMANN "Therapeutic Systems", F. Enke Verlag Stuttgart, 1984, p. 26). Therapeutic systems can be used both for topical and for systemic applications and are accordingly designed differently.
  • a transdermal therapeutic system according to the invention is characterized, among other things, by the following advantages:
  • the active substance gets directly into the body's circulation, which means that the Metabolism in the gastrointestinal tract is avoided.
  • TTS containing the active ingredient (s) there are various possibilities for realizing a TTS containing the active ingredient (s) according to the invention, such as, for example, pressure-sensitive adhesive plasters, films, sprays, creams, ointments and the like.
  • the form of administration of the pressure-sensitive adhesive plasters is particularly preferred. They generally consist of an impermeable backing layer, an associated drug reservoir with a mostly polymeric matrix, in the absence of other control mechanisms, a membrane that controls the delivery of the drug, a pressure-sensitive adhesive device for attaching the system to the skin and, if necessary, a front the application of the system as a ready-to-use drug removable protective layer.
  • transdermal adhesive pressure-sensitive plasters which are useful for the invention are known to the person skilled in the art from the prior art. They can largely be assigned to two basic control principles: matrix diffusion control and membrane control, only the latter having a zero-order release of active ingredient.
  • matrix diffusion control is e.g. described in DE-PS 33 15 272. It consists of an impermeable backing layer, an associated, specially constructed reservoir made of a polymer matrix, which contains the active ingredient
  • REPLACEMENT SADDLE contains a concentration above the saturation concentration, an adhesive layer which is connected to the reservoir and is permeable to the active ingredient, and a protective layer which covers the pressure-sensitive adhesive layer and can be removed again for use. If the reservoir matrix itself is already pressure-sensitive adhesive, the additional pressure-sensitive adhesive layer can be dispensed with.
  • plasters with membrane control reference is made, for example, to US Pat. No. 3,598,122. These plasters basically consist of a backing layer which represents one of the surfaces, an adhesive layer which is permeable to the active substance and which represents the other surface, and finally a reservoir which contains the active substance between the layers forming the two surfaces.
  • the active ingredient can also be contained in a multiplicity of microcapsules which are distributed within the permeable adhesive layer.
  • the active ingredient is continuously released from the reservoir or the microcapsules through a membrane into the adhesive layer which is permeable to the active ingredient and which is in contact with the skin of the person to be treated.
  • the capsule material can also act as a membrane.
  • the plasters may contain various types of additives in addition to the matrix forming the reservoir and the active substance or combinations of active substances. Additives that diffuse the active substance in the reservoir are particularly mentioned
  • REPLACEMENT LATCH (RULE 26) and / or influence the permeation of the active ingredient through the skin.
  • Such additives are known to the person skilled in the art in this field.
  • Active substances which are suitable for the invention are primarily CO-containing complex compounds which come under the generic term of coordination compounds.
  • the CO is represented as a ligand linked to a central atom.
  • the add-on complexes are preferred to the penetration complexes.
  • These add-on complexes generally represent solid or liquid substances which can be handled without problems by weight and can therefore be incorporated into a TTS in a defined concentration.
  • These coordination compounds have at least one CO ligand, there being multinuclear representatives which, for example, have bound up to 12 CO. In addition to the CO, other ligands can also be bound to the central atom. Multinuclear coordination compounds are to be understood as those which have more than one central atom. They are also suitable for the purposes of the invention.
  • Coordination compounds with metals of the sixth to eighth subgroup of the periodic table as the central atom are particularly preferred, the iron pentacarbonyl and the iron neacarbonyl enjoying a preferred position.
  • those compounds are also suitable which, in addition to CO, contain further ligands known from the chemistry of coordinate compounds.
  • an effective amount of active ingredient is introduced into the system in solid or liquid form, in solution or in dispersion, it being possible to use customary additives.
  • the selection of the components, the structure, the design and the effectiveness Concentrations of substances depend on the nature of the active ingredient and the desired effect, so that no generally valid information is possible.
  • TTS tetrachloro-2-amino-2-amino-2-amino-2-amino-2-amino-2-amino-2-amino-2-amino-2-amino-2-amino-2-amino-2-amino-2-amino-2-amino-2-amino-2-amino-2-amino-2-amino-2-amino-2-amino-2-astyroxine sulfate, urethane, urethane, urethane, urethane, urethane, urethane, urethane, urethane, urethane, urethane, urethane, urethane, urethane, urethane-N-amino-2-amino-2-amino-2-amino-2-amino-2-amino-2-amino-2-amino-2-amino-2-amino-2-amino-2-amino-2
  • Active ingredient selection Active ingredient combination Control of the release Release rate Composition of the reservoir Stabilization Enhancer addition Thickness of the layers Design of the back layer Dimensioning

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Preparation (AREA)

Abstract

Un système thérapeutique transdermique (STT) contient des composés qui libèrent du monoxyde de carbone dans l'organisme afin d'augmenter la concentration en CO de l'organisme.
EP95921826A 1994-06-18 1995-06-03 Systeme therapeutique transdermique a principes actifs constituant des sources de monoxyde de carbone Ceased EP0766558A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE4421433A DE4421433C1 (de) 1994-06-18 1994-06-18 Transdermales therapeutisches System mit Wirkstoffen, die Kohlenmonoxid-Quellen darstellen, Verfahren zu seiner Herstellung und seine Verwendung
DE4421433 1994-06-18
PCT/EP1995/002119 WO1995035105A1 (fr) 1994-06-18 1995-06-03 Systeme therapeutique transdermique a principes actifs constituant des sources de monoxyde de carbone

Publications (1)

Publication Number Publication Date
EP0766558A1 true EP0766558A1 (fr) 1997-04-09

Family

ID=6520976

Family Applications (1)

Application Number Title Priority Date Filing Date
EP95921826A Ceased EP0766558A1 (fr) 1994-06-18 1995-06-03 Systeme therapeutique transdermique a principes actifs constituant des sources de monoxyde de carbone

Country Status (6)

Country Link
US (1) US5882674A (fr)
EP (1) EP0766558A1 (fr)
JP (1) JPH10501539A (fr)
CA (1) CA2193100A1 (fr)
DE (1) DE4421433C1 (fr)
WO (1) WO1995035105A1 (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1829550A3 (fr) * 1996-09-27 2008-04-30 The Trustees of Columbia University in the City of New York Procédés pour le traitement d'un trouble ischémique et améliorer les suites d'un accident vasculaire cérébral
US8128963B2 (en) 1996-09-27 2012-03-06 The Trustees Of Columbia University In The City Of New York Methods for treating ischemic disorders using carbon monoxide
US7678390B2 (en) 1999-04-01 2010-03-16 Yale University Carbon monoxide as a biomarker and therapeutic agent
GB0111872D0 (en) * 2001-05-15 2001-07-04 Northwick Park Inst For Medica Therapeutic agents and methods
MXPA03012031A (es) 2001-06-21 2005-07-01 Univ Yale El monoxido de carbono mejoraresultados en transplantes de tejido y organo y suprime apoptosis.
US7968605B2 (en) * 2002-02-04 2011-06-28 ALFAMA—Investigação e Desenvolvimento de Produtos Farmacêuticos, Lda. Methods for treating inflammatory disease by administering aldehydes and derivatives thereof
US20080026984A1 (en) * 2002-02-04 2008-01-31 Alfama - Investigacao E Desenvolvimento De Productos Farmaceuticos Lda Methods for treating inflammatory disease by administering aldehydes and derivatives thereof
US7011854B2 (en) * 2002-02-04 2006-03-14 Alfama-Investigacao e Desenvolvimento de Produtos Farmaceuticos Lda Method for treating a mammal by administration of a compound having the ability to release CO, compounds having the ability to release CO and pharmaceutical compositions thereof
AU2003211102B2 (en) 2002-02-13 2010-03-04 Beth Israel Deaconess Medical Center, Inc. Methods of treating vascular disease
PL374241A1 (en) 2002-04-15 2005-10-03 University Of Pittsburgh Of The Commonwealth System Of Higher Education Methods of treating necrotizing enterocolitis
JP4588325B2 (ja) 2002-04-15 2010-12-01 ユニバーシティ オブ ピッツバーグ オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション イレウスの治療方法
US8097585B2 (en) 2002-04-15 2012-01-17 Beth Israel Deaconess Medical Center, Inc. Methods of treating inflammation by administration of heme oxygenase-1 and products of heme degradation
CN1638781A (zh) * 2002-05-09 2005-07-13 耶鲁大学 一氧化碳作为生物标记物和治疗剂
MXPA04011426A (es) 2002-05-17 2005-10-19 Univ Yale Metodo para tratar la hepatitis.
MXPA04012167A (es) * 2002-06-05 2005-09-21 Univ Yale Metodos para tratar angiogenesis, crecimeinto tumoral y metastasis.
PL375161A1 (en) * 2002-06-21 2005-11-28 University Of Pittsburgh Of The Commonwealth System Of Higher Education Pharmaceutical use of nitric oxide, heme oxygenase-1 and products of heme degradation
US20040228930A1 (en) * 2002-11-07 2004-11-18 Billiar Timothy R. Treatment for hemorrhagic shock
GB2395432B (en) * 2002-11-20 2005-09-14 Northwick Park Inst For Medica Therapeutic delivery of carbon monoxide to extracorporeal and isolated organs
GB2395431A (en) * 2002-11-20 2004-05-26 Northwick Park Inst For Medica Combination of a metal carbonyl compound and a guanylate cyclase stimulant or stabilizer for the therapeutic delivery of carbon monoxide
US20070207217A1 (en) * 2003-02-03 2007-09-06 Alfama - Investigacao E Desenvolvimento De Productos Farmaceuticos Lda Method for treating a mammal by administration of a compound having the ability to release CO
EP1731150A4 (fr) * 2004-03-04 2010-06-16 Makoto Yuasa Niosome ayant un complexe porphyrine metallique y incorporee, procede pour la production de celle-ci et medicament utilisant celui-ci
GB0601394D0 (en) 2006-01-24 2006-03-01 Hemocorm Ltd Therapeutic delivery of carbon monoxide
DE102010014411A1 (de) * 2010-04-08 2011-10-13 Friedrich-Schiller-Universität Jena Kohlenmonoxid und Eisen freisetzende Moleküle, deren Verwendung und Verfahren zu deren Herstellung
DE102010014412A1 (de) 2010-04-08 2012-04-19 Friedrich-Schiller-Universität Jena Verwendung von zweikernigen Eisenkomplexen mit schwefelhaltigen Liganden als pharmakologische Wirkstoffe
WO2012115984A2 (fr) 2011-02-21 2012-08-30 Felice Kristopher M Dispersions de polyuréthane et leurs procédés de fabrication et d'utilisation
PT2699242T (pt) 2011-04-19 2018-01-22 Alfama Inc Moléculas de libertação de monóxido de carbono e utilizações das mesmas
CN103703086A (zh) 2011-06-10 2014-04-02 克里斯托弗·M·费利斯 透明涂层，丙烯酸类涂层
ES2628634T3 (es) 2011-07-21 2017-08-03 Alfama, Inc. Moléculas liberadoras de monóxido de carbono-rutenio y usos de las mismas
DE102012004132A1 (de) 2012-02-29 2013-08-29 Friedrich-Schiller-Universität Jena Kohlenstoffmonoxid freisetzende Materialien und deren Verwendung
DE102014008685A1 (de) * 2014-06-13 2015-12-17 Lorenz Meinel Freisetzungssystem für therapeutisches Gas
PT3242552T (pt) * 2015-01-08 2021-07-12 Univ Wuerzburg J Maximilians Dispositivo de distribuição de gás que compreende uma molécula de libertação de gás e uma membrana permeável a gás
EP3878471A1 (fr) * 2020-03-13 2021-09-15 Julius-Maximilians-Universitaet Wuerzburg Système thérapeutique pour l'application topique, transdermique et transcutanée de monoxyde de carbone

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3598122A (en) * 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
DE3315272C2 (de) * 1983-04-27 1986-03-27 Lohmann Gmbh & Co Kg, 5450 Neuwied Pharmazeutisches Produkt und Verfahren zu seiner Herstellung
US4708716A (en) * 1983-08-18 1987-11-24 Drug Delivery Systems Inc. Transdermal drug applicator
US4687481A (en) * 1984-10-01 1987-08-18 Biotek, Inc. Transdermal drug delivery system
US5086060A (en) * 1989-07-25 1992-02-04 Eastman Kodak Company Compound and method for treating skin for acne or psoriasis
JPH04500824A (ja) * 1989-07-25 1992-02-13 イーストマン コダック カンパニー 光老化の作用を回復させるための皮膚の治療方法
US5308625A (en) * 1992-09-02 1994-05-03 Cygnus Therapeutic Systems Enhancement of transdermal drug delivery using monoalkyl phosphates and other absorption promoters

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9535105A1 *

Also Published As

Publication number Publication date
CA2193100A1 (fr) 1995-12-28
JPH10501539A (ja) 1998-02-10
DE4421433C1 (de) 1995-06-08
WO1995035105A1 (fr) 1995-12-28
US5882674A (en) 1999-03-16

Similar Documents

Publication Publication Date Title
DE4421433C1 (de) Transdermales therapeutisches System mit Wirkstoffen, die Kohlenmonoxid-Quellen darstellen, Verfahren zu seiner Herstellung und seine Verwendung
AU2016267585B2 (en) Stable cannabinoid formulations
EP0617623B1 (fr) Systeme d'administration transdermique contenant de l'acide acetylsalicylique pour la therapie antithrombotique
DE10230165A1 (de) Verfahren und Vorrichtung zur Administration von Kohlenmonoxid
EP1467706A2 (fr) Systeme d'administration dermique de derives d'acide aminolevulique
DE3390091C1 (de) Krampfstillendes Praeparat aus einem auf der Haut befestigbaren Pflaster,Verfahren zu dessen Herstellung sowie dessen Verwendung
EP0387693B1 (fr) Système transdermique de libération de médicament par paliers et son utilisation pour l'administration locale ou systémique de produits cosmétiques
DE4305881C1 (de) Transdermales therapeutisches System mit Wirkstoffen, welche Stichoxid-Quellen darstellen, Verfahren zu seiner Herstellung sowie seine Verwendung
DE3115080C2 (de) Arzneimittel enthaltend Cytidindiphosphocholin und Lecithin
DE3727585C2 (de) Nicorandil enthaltende Arzneimittel zur äußeren Anwendung
DE10034673C1 (de) Dermales Applikationssystem für Aminolävulinsäure und seine Verwendung
DE10004790A1 (de) Transdermales therapeutisches System zur Verabreichung von Zaleplon
DE10228680A1 (de) Grundlage für transdermale Formulierungen (PTF)
DE3825374C2 (fr)
DE68916958T2 (de) Topisch angebrachter goldorganokomplex.
WO1996030003A1 (fr) Medicaments pour le traitement selectif des tissus affectes par des tumeurs
EP0668074B1 (fr) Système thérapeutique transdermique
EP0671916A1 (fr) Systeme d'administration transdermique contenant de l'acide acetylsalicylique pour la therapie antithrombotique et la prophylaxie contre le cancer
EP1121126A1 (fr) Procede pour traiter la schizophrenie et substance utilisee dans le cadre de ce procede
EP1480614B1 (fr) Emulsion contenant des gouttes hydrophobes de l'ordre du nanometre avec des molecules d'hemoglobine liees en phase hydrophile, utilisee comme substitut du sang
AT389049B (de) Verfahren zur herstellung von an der unverletzten haut befestigbaren pharmazeutischen paeparaten, insbesondere von muskelkrampfloesenden und antirheumatischen praeparaten
Windorfer et al. Untersuchungen über die Medikamenten-Serumspiegel antikonvulsiv behandelter Kinder
DE3543974A1 (de) Arzneimittel zur bekaempfung von durchblutungsstoerungen
WO1994013302A1 (fr) Systeme d'administration transdermique contenant de l'acide acetylsalicylique pour la therapie antithrombotique et la prophylaxie contre le cancer
DE19750287A1 (de) Homöopathisches Arzneimittel zur Entgiftung des Körpers von Quecksilber aus Amalgam-Zahnfüllungen

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19961204

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE

AX Request for extension of the european patent

Free format text: SI PAYMENT 961204

17Q First examination report despatched

Effective date: 19990929

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: LTS LOHMANN THERAPIE-SYSTEME AG

RIC1 Information provided on ipc code assigned before grant

Free format text: 7A 61K 31/295 A, 7A 61K 9/70 B, 7A 61P 9/00 B

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

RIC1 Information provided on ipc code assigned before grant

Free format text: 7A 61K 31/295 A, 7A 61K 9/70 B, 7A 61P 9/00 B

RIC1 Information provided on ipc code assigned before grant

Free format text: 7A 61K 31/295 A, 7A 61K 9/70 B, 7A 61P 9/00 B

RIC1 Information provided on ipc code assigned before grant

Free format text: 7A 61K 31/295 A, 7A 61K 9/70 B, 7A 61P 9/00 B

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20020125